J&J plans job cuts, $800 million charge
Article Abstract:
Johnson & Johnson announced its plans to close 36 factories and cut more than 4,000 jobs in the next 18 months. Sales growth has been very week considering its past history and strength in the marketplace. The plant closings will be primarily where medical devices and consumer products are manufactured. R&D expenses are anticipated to go to $2.5 billion in 1999, so the company will apply some of its cost savings there. Savings are expected to be in the range of $200 million to $300 million per year, but not be realized for a year or two. At least one analyst feels the company will have to do more in the way of cuts in order to make a difference in the longer term.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Drug to lower cholesterol gets boost in study
Article Abstract:
A study on patients with only mild symptoms of heart disease and with blockages in only one or two arteries are the best candidates for treatment with Lipitor. The drug is in the class called statins and lowers "bad" or LDL cholesterol. The study showed that the drug is a more effective treatment than angioplasty. The study also showed that most of the benefit from Lipitor was fewer hospital admissions for severe chest pain. The drug is made by Warner-Lambert Co. The company also funded this particular study. Lipitor is co-marketed by Pfizer.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Protests held against Windows system. Gates hits $100 billion mark, more or less. 'Microsofties' say they're right as rain
- Abstracts: Xtra to be sold for $976 million to group led by Interpool, Apollo. Cendant CEO's wealth melts with share price
- Abstracts: Kaiser decides not to cover Viagra pills. HMOs' image worries spur campaigns. Hydraulics and computers help artificial limbs get 'smarter'